1. Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1( 2H )-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma.
- Author
-
Li QQ, Quan X, Wang ZX, Qiao N, Ni XF, Jing XL, Zhou SS, Tian XL, Zheng GC, Zhan KN, Xu YJ, Yang J, Zhou Y, Liang XT, Zhao ZH, Wei TH, Liu Q, Bai MY, Sun SL, Yu YC, Cao P, Li NG, Zhang XM, Liu J, and Shi ZH
- Subjects
- Humans, Animals, Structure-Activity Relationship, Cell Line, Tumor, Cell Proliferation drug effects, Mice, Molecular Docking Simulation, Enzyme Inhibitors pharmacology, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacokinetics, Enzyme Inhibitors therapeutic use, Apoptosis drug effects, Xenograft Model Antitumor Assays, Mice, Nude, Male, Protein-Arginine N-Methyltransferases antagonists & inhibitors, Protein-Arginine N-Methyltransferases metabolism, Drug Design, Isoquinolines pharmacology, Isoquinolines chemistry, Isoquinolines chemical synthesis, Isoquinolines pharmacokinetics, Isoquinolines therapeutic use, Antineoplastic Agents pharmacology, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacokinetics, Lymphoma, Non-Hodgkin drug therapy, Lymphoma, Non-Hodgkin pathology
- Abstract
Through catalyzing the transfer of methyl groups onto the guanidinium of arginine, protein arginine methyltransferase 5 (PRMT5) was essential to the cell growth of cancer cells. By utilizing a scaffold hopping strategy, a novel series of 3,4-dihydroisoquinolin-1( 2H )-one derivatives were designed and synthesized. Through a systematic SAR study, D3 demonstrated excellent PRMT5 inhibitory activity, potent antiproliferative activity against Z-138, favorable pharmacokinetic profiles, and low hERG toxicity. Molecular docking, molecular dynamic (MD) simulation, and surface plasmon resonance (SPR) study indicated that D3 was tightly interacted with PRMT5. Meanwhile, D3 exhibited high selectivity against PRMT5, which could inhibit the growth of various cancer cells, induce apoptosis, and arrest the cell cycle in the G0/G1 phase. Additionally, D3 possessed excellent antitumor efficacy in Z-138 xenograft models, low toxicity in vivo , and acceptable drug metabolism and pharmacokinetics (DMPK) profiles in vitro . Therefore, D3 can be developed as a promising candidate for the treatment of non-Hodgkin's lymphoma (NHL).
- Published
- 2025
- Full Text
- View/download PDF